Eisai’s BACE Inhibitor Cuts Beta Amyloid by 70% at 50 mg Daily

Eisai said on December 12 that its oral BACE inhibitor elenbecestat (development code: E2609), which is being developed for early-phase Alzheimer’s disease, is predicted to have reduced cerebrospinal fluid (CSF) beta amyloid (Aβ) by a median 70% at a daily...read more